1
|
Yin X, Cicali B, Rodriguez-Vera L, Lukacova V, Cristofoletti R, Schmidt S. Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine's Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes. Pharmaceutics 2024; 16:737. [PMID: 38931859 PMCID: PMC11206836 DOI: 10.3390/pharmaceutics16060737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2024] [Revised: 05/21/2024] [Accepted: 05/24/2024] [Indexed: 06/28/2024] Open
Abstract
Carbamazepine (CBZ) is commonly prescribed for epilepsy and frequently used in polypharmacy. However, concerns arise regarding its ability to induce the metabolism of other drugs, including itself, potentially leading to the undertreatment of co-administered drugs. Additionally, CBZ exhibits nonlinear pharmacokinetics (PK), but the root causes have not been fully studied. This study aims to investigate the mechanisms behind CBZ's nonlinear PK and its induction potential on CYP3A4 and CYP2C9 enzymes. To achieve this, we developed and validated a physiologically based pharmacokinetic (PBPK) parent-metabolite model of CBZ and its active metabolite Carbamazepine-10,11-epoxide in GastroPlus®. The model was utilized for Drug-Drug Interaction (DDI) prediction with CYP3A4 and CYP2C9 victim drugs and to further explore the underlying mechanisms behind CBZ's nonlinear PK. The model accurately recapitulated CBZ plasma PK. Good DDI performance was demonstrated by the prediction of CBZ DDIs with quinidine, dolutegravir, phenytoin, and tolbutamide; however, with midazolam, the predicted/observed DDI AUClast ratio was 0.49 (slightly outside of the two-fold range). CBZ's nonlinear PK can be attributed to its nonlinear metabolism caused by autoinduction, as well as nonlinear absorption due to poor solubility. In further applications, the model can help understand DDI potential when CBZ serves as a CYP3A4 and CYP2C9 inducer.
Collapse
Affiliation(s)
- Xuefen Yin
- Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA; (X.Y.); (B.C.); (L.R.-V.)
| | - Brian Cicali
- Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA; (X.Y.); (B.C.); (L.R.-V.)
| | - Leyanis Rodriguez-Vera
- Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA; (X.Y.); (B.C.); (L.R.-V.)
| | | | - Rodrigo Cristofoletti
- Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA; (X.Y.); (B.C.); (L.R.-V.)
| | - Stephan Schmidt
- Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA; (X.Y.); (B.C.); (L.R.-V.)
| |
Collapse
|
2
|
Arce F, Schuman Y, Gawel J, Garmise R, Abebe A, Desai D. An Evaluation of Wet Granulation Process Selection for API Prone to Polymorphic Form Conversion in the Presence of Moisture and Heat. Pharm Res 2024; 41:595-607. [PMID: 38383934 DOI: 10.1007/s11095-024-03667-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Accepted: 01/22/2024] [Indexed: 02/23/2024]
Abstract
PURPOSE Wet granulation (WG) is one of the most versatile processes to improve blend properties for processing. However, due to its need for moisture and heat, it is often considered not amenable to active pharmaceutical ingredients (APIs) prone to forming hydrates. Despite this claim, little literature exists evaluating the extent to which polymorphic form conversions occur for such API when processed with WG. This work sets out to explore two common WG methods, high-shear (HSG) and fluid-bed (FBG), and two drying processes, tray-drying (TD) and fluid-bed drying (FBD), and evaluate the risk they pose to hydrate form conversion. METHODS The progression of anhydrous to hydrate form conversion of two model compounds with vastly different solubilities, fexofenadine hydrochloride and carbamazepine, was monitored throughout the various processes using powder X-ray diffraction. The resultant granules were characterized using thermogravimetric analysis, differential scanning calorimetry, BET adsorption, and sieve analysis. RESULTS FBG and FBD processing resulted in the preservation of the original form of both APIs, while HSG+TD resulted in the complete conversion of the API. The FBD of fexofenadine and carbamazepine granules prepared with HSG resulted in partial and complete re-conversion back to the original anhydrous forms, respectively. CONCLUSION The drying process is a critical factor in anhydrous form conservation. FBG and FBD yielded better preservation of the initial anhydrous forms. HSG could be an acceptable granulation method for API susceptible to hydrate formation if the API solubility is low. Selecting an FBG+FBD process minimizes API hydrate formation and preserves the original anhydrous form.
Collapse
Affiliation(s)
- Freddy Arce
- Drug Product Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, 08901, NJ, USA.
| | - Yue Schuman
- Drug Product Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, 08901, NJ, USA
| | - John Gawel
- Drug Product Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, 08901, NJ, USA
| | - Robert Garmise
- Drug Product Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, 08901, NJ, USA
| | - Admassu Abebe
- Drug Product Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, 08901, NJ, USA
| | - Divyakant Desai
- Drug Product Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, 08901, NJ, USA
| |
Collapse
|
3
|
Fateixa S, Nogueira HIS, Paixão JA, Fausto R, Trindade T. Insightful vibrational imaging study on the hydration mechanism of carbamazepine. Phys Chem Chem Phys 2022; 24:19502-19511. [PMID: 35938321 DOI: 10.1039/d2cp02185d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Anhydrous carbamazepine (CBZ) is an anti-convulsant drug commonly used to treat epilepsy and relieve trigeminal neuralgia. The presence of the dihydrate form in commercial CBZ tablets can change the dissolution rate of the active pharmaceutical ingredient (API), thus decreasing its activity. The hydration transformation can occur during wet granulation or storage, within a few weeks, depending on the ambient conditions. This work aims to investigate the effect of relative humidity (RH) in the transition of pure anhydrous CBZ (CBZ III) into the hydrate form by using confocal Raman microscopy with cluster analysis (CA). Firstly, several tablets of pure CBZ III containing different amounts of CBZ DH (50%, 10%, 1%, 0.5%) were prepared and analyzed by Raman imaging with CA. Our results show that CBZ DH crystals can be detected in the CBZ III tablets, at as low a concentration as 0.5%, giving distinct Raman features for the analysed polymorphs. The stability of pure anhydrous (CBZ III) tablets was then monitored by Raman imaging at room temperature (20-22 °C) and different RH (6%, 60% and 89%). The Raman imaging with CA showed that the anhydrous CBZ tablets start to convert into the hydrate form after 48 h, and it completely changes after 120 hours (5 days) at RH 89%. The tablets exposed to RH 6% and 60% did not demonstrate the presence of CBZ DH after 1 week of exposure. The exposure time was extended for 9 months in the former, and no CBZ DH was observed. A comparative study using IR imaging was also performed, demonstrating the viability of these vibrational imaging techniques as valuable tools to monitor the hydration process of active pharmaceutical ingredients.
Collapse
Affiliation(s)
- Sara Fateixa
- Department of Chemistry and CICECO-Aveiro Institute of Materials, University of Aveiro, 3810-193 Aveiro, Portugal.
| | - Helena I S Nogueira
- Department of Chemistry and CICECO-Aveiro Institute of Materials, University of Aveiro, 3810-193 Aveiro, Portugal.
| | - José A Paixão
- CFisUC, Department of Physics, University of Coimbra, P-3004-516 Coimbra, Portugal
| | - Rui Fausto
- CQC-IMS, Department of Chemistry, University of Coimbra, P-3004-535 Coimbra, Portugal
| | - Tito Trindade
- Department of Chemistry and CICECO-Aveiro Institute of Materials, University of Aveiro, 3810-193 Aveiro, Portugal.
| |
Collapse
|
4
|
Elmer S, Reddy DS. Therapeutic Basis of Generic Substitution of Antiseizure Medications. J Pharmacol Exp Ther 2022; 381:188-196. [PMID: 35241634 PMCID: PMC9132097 DOI: 10.1124/jpet.121.000994] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Accepted: 02/25/2022] [Indexed: 11/22/2022] Open
Abstract
More than thirty antiseizure medications (ASMs) are available for treating epilepsy. ASMs differ in their potency and efficacy in controlling seizures by acting on diverse targets in the brain, often with variable pharmacokinetics. Moreover, nearly 30% of people with epilepsy have drug-resistant or intractable seizures. Generic substitution of ASMs is a complex issue. It is thought that frequent generic substitution in people with epilepsy may cause problems because the U.S. Food and Drug Administration (FDA) rules allow too much variability across products. The standard bioequivalence range (80% to 125%) appears too broad for many ASMs, especially those exhibiting little separation between therapeutic and toxic levels. Hence, sub-therapeutic concentration may lead to therapeutic failure with seizure recurrence, which could be life threatening. A supra-therapeutic level could result in adverse effects or compliance issues. There are reported issues with generic substitutions of phenytoin, topiramate, levetiracetam, carbamazepine, and lamotrigine. There is discussion in the epilepsy community about additional guidelines, including designation of generic ASMs as Narrow Therapeutic Index (NTI) drugs and how patient education plays a role in generic substitution. Overall, based on the published evidence on specific generic ASMs, FDA bioequivalence standards are not the cause of problems with generic ASM substitution. Rather, it is imperative that physicians and pharmacists provide adequate patient education on what to expect when switching to generic ASMs, including changes in medication shape and color. Another suggestion would be to consider that all ASMs be considered for inclusion in NTI class to prevent the clinical outcome issues associated with generic ASM switching. SIGNIFICANCE STATEMENT: There are critical aspects to consider when switching from a brand name antiseizure medication (ASM) when a generic becomes available or switching between generics. Generic ASMs are interchanged with little consideration of differences in therapeutic equivalence and other clinical factors. This article describes key issues on generic substitution of ASMs and highlights critical pharmacotherapeutic issues associated with generic ASMs.
Collapse
Affiliation(s)
- Sarah Elmer
- Department of Neuroscience and Experimental Therapeutics, Texas A&M University Health Science Center College of Medicine, Bryan, Texas
| | - Doodipala Samba Reddy
- Department of Neuroscience and Experimental Therapeutics, Texas A&M University Health Science Center College of Medicine, Bryan, Texas
| |
Collapse
|
5
|
Fateixa S, Nogueira HIS, Trindade T. Carbamazepine polymorphism: a re-visitation using Raman imaging. Int J Pharm 2022; 617:121632. [PMID: 35245634 DOI: 10.1016/j.ijpharm.2022.121632] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 02/25/2022] [Accepted: 02/28/2022] [Indexed: 10/19/2022]
Abstract
Raman imaging methods have appeared in the last years as a powerful approach to monitoring the quality of pharmaceutical compounds. Because polymorphism occurs in many crystalline pharmaceutical compounds, it is essential to monitor polymorphic transformations induced by different external stimulus, such as temperature changes, to which those compounds may be submitted. Raman imaging with k-means cluster analysis (CA) is used here as an essential technique to investigate structural and chemical transformations occurring in carbamazepine p-monoclinic (CBZ III) into carbamazepine triclinic (CBZ I) when submitted to temperatures near the melting point of CBZ III (178 °C) and CBZ I (193°C). CBZ III commercial powder and laboratorial prepared CBZ I were analyzed by differential scanning calorimetry, powder X-ray diffraction and Raman spectroscopy with variable temperature. After thermal treatment, the resultant CBZ powder was evaluated by Raman imaging, in which all imaging data was analyzed using CA. Raman imaging allowed the identification of different polymorphs of CBZ (CBZ III and CBZ I) and iminostilbene (IMS), a degradation product of CBZ, in the treated samples, depending on the heating treatment method.
Collapse
Affiliation(s)
- Sara Fateixa
- Department of Chemistry and CICECO-Aveiro Institute of Materials, University of Aveiro, 3810-193 Aveiro, Portugal.
| | - Helena I S Nogueira
- Department of Chemistry and CICECO-Aveiro Institute of Materials, University of Aveiro, 3810-193 Aveiro, Portugal
| | - Tito Trindade
- Department of Chemistry and CICECO-Aveiro Institute of Materials, University of Aveiro, 3810-193 Aveiro, Portugal
| |
Collapse
|
6
|
Park H, Kim JS, Hong S, Ha ES, Nie H, Zhou QT, Kim MS. Tableting process-induced solid-state polymorphic transition. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2022. [DOI: 10.1007/s40005-021-00556-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
7
|
Schneider-Rauber G, Arhangelskis M, Goh WP, Cattle J, Hondow N, Drummond-Brydson R, Ghadiri M, Sinha K, Ho R, Nere NK, Bordawekar S, Sheikh AY, Jones W. Understanding stress-induced disorder and breakage in organic crystals: beyond crystal structure anisotropy. Chem Sci 2021; 12:14270-14280. [PMID: 34760213 PMCID: PMC8565387 DOI: 10.1039/d1sc03095g] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Accepted: 10/08/2021] [Indexed: 11/29/2022] Open
Abstract
Crystal engineering has advanced the strategies for design and synthesis of organic solids with the main focus being on customising the properties of the materials. Research in this area has a significant impact on large-scale manufacturing, as industrial processes may lead to the deterioration of such properties due to stress-induced transformations and breakage. In this work, we investigate the mechanical properties of structurally related labile multicomponent solids of carbamazepine (CBZ), namely the dihydrate (CBZ·2H2O), a cocrystal of CBZ with 1,4-benzoquinone (2CBZ·BZQ) and the solvates with formamide and 1,4-dioxane (CBZ·FORM and 2CBZ·DIOX, respectively). The effect of factors that are external (e.g. impact stressing) and/or internal (e.g. phase transformations and thermal motion) to the crystals are evaluated. In comparison to the other CBZ multicomponent crystal forms, CBZ·2H2O crystals tolerate less stress and are more susceptible to breakage. It is shown that this poor resistance to fracture may be a consequence of the packing of CBZ molecules and the orientation of the principal molecular axes in the structure relative to the cleavage plane. It is concluded, however, that the CBZ lattice alone is not accountable for the formation of cracks in the crystals of CBZ·2H2O. The strength and the temperature-dependence of electrostatic interactions, such as hydrogen bonds between CBZ and coformer, appear to influence the levels of stress to which the crystals are subjected that lead to fracture. Our findings show that the appropriate selection of coformer in multicomponent crystal forms, targetting superior mechanical properties, needs to account for the intrinsic stress generated by molecular vibrations and not solely by crystal anisotropy. Structural defects within the crystal lattice, although highly influenced by the crystallisation conditions and which are especially difficult to control in organic solids, may also affect breakage.
Collapse
Affiliation(s)
| | - Mihails Arhangelskis
- Faculty of Chemistry, University of Warsaw 1 Pasteura Street Warsaw 02-093 Poland
| | - Wei-Pin Goh
- School of Chemical and Process Engineering, University of Leeds Leeds LS2 9JT UK
| | - James Cattle
- School of Chemical and Process Engineering, University of Leeds Leeds LS2 9JT UK
| | - Nicole Hondow
- School of Chemical and Process Engineering, University of Leeds Leeds LS2 9JT UK
| | - Rik Drummond-Brydson
- School of Chemical and Process Engineering, University of Leeds Leeds LS2 9JT UK
| | - Mojtaba Ghadiri
- School of Chemical and Process Engineering, University of Leeds Leeds LS2 9JT UK
| | - Kushal Sinha
- Process Research and Development, AbbVie, Inc. North Chicago IL USA
| | - Raimundo Ho
- Process Research and Development, AbbVie, Inc. North Chicago IL USA
| | | | | | - Ahmad Y Sheikh
- Process Research and Development, AbbVie, Inc. North Chicago IL USA
| | - William Jones
- Department of Chemistry, University of Cambridge Cambridge CB2 1EW UK
| |
Collapse
|
8
|
Pawar G, Wu F, Zhao L, Fang L, Burckart GJ, Feng K, Mousa YM, Naumann F, Batchelor HK. Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral Products. AAPS JOURNAL 2021; 23:57. [PMID: 33884497 PMCID: PMC8060189 DOI: 10.1208/s12248-021-00592-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Accepted: 04/06/2021] [Indexed: 01/01/2023]
Abstract
Generally, bioequivalence (BE) studies of drug products for pediatric patients are conducted in adults due to ethical reasons. Given the lack of direct BE assessment in pediatric populations, the aim of this work is to develop a database of BE and relative bioavailability (relative BA) studies conducted in pediatric populations and to enable the identification of risk factors associated with certain drug substances or products that may lead to failed BE or different pharmacokinetic (PK) parameters in relative BA studies in pediatrics. A literature search from 1965 to 2020 was conducted in PubMed, Cochrane Library, and Google Scholar to identify BE studies conducted in pediatric populations and relative BA studies conducted in pediatric populations. Overall, 79 studies covering 37 active pharmaceutical ingredients (APIs) were included in the database: 4 bioequivalence studies with data that passed BE evaluations; 2 studies showed bioinequivalence results; 34 relative BA studies showing comparable PK parameters, and 39 relative BA studies showing differences in PK parameters between test and reference products. Based on the above studies, common putative risk factors associated with differences in relative bioavailability (DRBA) in pediatric populations include age-related absorption effects, high inter-individual variability, and poor study design. A database containing 79 clinical studies on BE or relative BA in pediatrics has been developed. Putative risk factors associated with DRBA in pediatric populations are summarized.
Collapse
Affiliation(s)
- Gopal Pawar
- School of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Edgbaston, B15 2TT, UK.
| | - Fang Wu
- Division of Quantitative Methods and Modelling, Office of Research and Standard, Office of Generic Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, 20993, USA.
| | - Liang Zhao
- Division of Quantitative Methods and Modelling, Office of Research and Standard, Office of Generic Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, 20993, USA
| | - Lanyan Fang
- Division of Quantitative Methods and Modelling, Office of Research and Standard, Office of Generic Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, 20993, USA
| | - Gilbert J Burckart
- Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, 20993, USA
| | - Kairui Feng
- Division of Quantitative Methods and Modelling, Office of Research and Standard, Office of Generic Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, 20993, USA
| | - Youssef M Mousa
- Division of Quantitative Methods and Modelling, Office of Research and Standard, Office of Generic Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, 20993, USA
| | - Franci Naumann
- School of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Edgbaston, B15 2TT, UK
| | - Hannah K Batchelor
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, UK.
| |
Collapse
|
9
|
García MA, Cristofoletti R, Abrahamsson B, Groot DW, Parr A, Polli JE, Mehta M, Shah VP, Tomakazu T, Dressman JB, Langguth P. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine. J Pharm Sci 2021; 110:1935-1947. [PMID: 33610571 DOI: 10.1016/j.xphs.2021.02.019] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Revised: 01/28/2021] [Accepted: 02/03/2021] [Indexed: 10/22/2022]
Abstract
Literature relevant to assessing whether BCS-based biowaivers can be applied to immediate release (IR) solid oral dosage forms containing carbamazepine as the single active pharmaceutical ingredient are reviewed. Carbamazepine, which is used for the prophylactic therapy of epilepsy, is a non-ionizable drug that cannot be considered "highly soluble" across the range of pH values usually encountered in the upper gastrointestinal tract. Furthermore, evidence in the open literature suggests that carbamazepine is a BCS Class 2 drug. Nevertheless, the oral absolute bioavailability of carbamazepine lies between 70 and 78% and both in vivo and in vitro data support the classification of carbamazepine as a highly permeable drug. Since the therapeutic and toxic plasma level ranges overlap, carbamazepine is considered to have a narrow therapeutic index. For these reasons, a BCS based biowaiver for IR tablets of carbamazepine cannot be recommended. Interestingly, in nine out of ten studies, USP dissolution conditions (900 mL water with 1% SLS, paddle, 75 rpm) appropriately discriminated among bioinequivalent products and this may be a way forward to predicting whether a given formulation will be bioequivalent to the comparator product.
Collapse
Affiliation(s)
- Mauricio A García
- Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Rodrigo Cristofoletti
- Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA
| | | | - Dirk W Groot
- RIVM (National Institute for Public Health and the Environment), Bilthoven, the Netherlands
| | | | - James E Polli
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD, USA
| | - Mehul Mehta
- Division of Clinical Pharmacology, Centre for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA
| | - Vinod P Shah
- International Pharmaceutical Federation (FIP), The Hague, the Netherlands
| | - Tajiri Tomakazu
- Pharmaceutical Science & Technology Laboratories, Astellas Pharma Inc, Ibaraki, Japan
| | - Jennifer B Dressman
- Fraunhofer Institute of Translational Medicine and Pharmacology, ITMP, Institute of Pharmaceutical Technology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
| | - Peter Langguth
- Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany.
| |
Collapse
|
10
|
Echeverri JD, Alhajj MJ, Montero N, Yarce CJ, Barrera-Ocampo A, Salamanca CH. Study of In Vitro and In Vivo Carbamazepine Release from Coarse and Nanometric Pharmaceutical Emulsions Obtained via Ultra-High-Pressure Homogenization. Pharmaceuticals (Basel) 2020; 13:E53. [PMID: 32224877 PMCID: PMC7243108 DOI: 10.3390/ph13040053] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Revised: 03/21/2020] [Accepted: 03/23/2020] [Indexed: 11/17/2022] Open
Abstract
In the past decade, pharmaceutical nanotechnology has proven to be a promising alternative for improving the physicochemical and biopharmaceutical features for conventional pharmaceutical drug formulations. The goal of this study was to develop, characterize, and evaluate the in vitro and in vivo release of the model drug carbamazepine (CBZ) from two emulsified formulations with different droplet sizes (coarse and nanometric). Briefly, oil-in-water emulsions were developed using (i) Sacha inchi oil, ultrapure water, TweenTM 80, and SpanTM 80 as surfactants, (ii) methyl-paraben and propyl-paraben as preservatives, and (iii) CBZ as a nonpolar model drug. The coarse and nanometric emulsions were prepared by rotor-stator dispersion and ultra-high-pressure homogenization (UHPH), respectively. The in vitro drug release studies were conducted by dialysis, whereas the in vivo drug release was evaluated in New Zealand breed rabbits. The results showed that nanoemulsions were physically more stable than coarse emulsions, and that CBZ had a very low release for in vitro determination (<2%), and a release of 20% in the in vivo study. However, it was found that nanoemulsions could significantly increase drug absorption time from 12 h to 45 min.
Collapse
Affiliation(s)
- Juan D. Echeverri
- Programa de Maestría en Formulación de Productos Químicos y Derivados, Facultad de Ciencias Naturales, Universidad Icesi, Calle 18 No. 122-135, Cali 76003, Colombia;
| | - Maria J. Alhajj
- Laboratorio de Diseño y Formulación de Productos Químicos y Derivados, Facultad de Ciencias Naturales. Universidad Icesi, Calle 18 No. 122-135, Cali 76003, Colombia; (M.J.A.); (N.M.); (C.J.Y.)
| | - Nicolle Montero
- Laboratorio de Diseño y Formulación de Productos Químicos y Derivados, Facultad de Ciencias Naturales. Universidad Icesi, Calle 18 No. 122-135, Cali 76003, Colombia; (M.J.A.); (N.M.); (C.J.Y.)
| | - Cristhian J. Yarce
- Laboratorio de Diseño y Formulación de Productos Químicos y Derivados, Facultad de Ciencias Naturales. Universidad Icesi, Calle 18 No. 122-135, Cali 76003, Colombia; (M.J.A.); (N.M.); (C.J.Y.)
| | - Alvaro Barrera-Ocampo
- Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Naturales, Universidad Icesi, Calle 18 No. 122-135, Cali 76003, Colombia;
| | - Constain H. Salamanca
- Programa de Maestría en Formulación de Productos Químicos y Derivados, Facultad de Ciencias Naturales, Universidad Icesi, Calle 18 No. 122-135, Cali 76003, Colombia;
- Laboratorio de Diseño y Formulación de Productos Químicos y Derivados, Facultad de Ciencias Naturales. Universidad Icesi, Calle 18 No. 122-135, Cali 76003, Colombia; (M.J.A.); (N.M.); (C.J.Y.)
| |
Collapse
|
11
|
Chemometric Models for Quantification of Carbamazepine Anhydrous and Dihydrate Forms in the Formulation. J Pharm Sci 2019; 108:1211-1219. [DOI: 10.1016/j.xphs.2018.10.023] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Revised: 09/24/2018] [Accepted: 10/03/2018] [Indexed: 11/22/2022]
|
12
|
Thakral NK, Zanon RL, Kelly RC, Thakral S. Applications of Powder X-Ray Diffraction in Small Molecule Pharmaceuticals: Achievements and Aspirations. J Pharm Sci 2018; 107:2969-2982. [PMID: 30145209 DOI: 10.1016/j.xphs.2018.08.010] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Revised: 07/23/2018] [Accepted: 08/07/2018] [Indexed: 10/28/2022]
Abstract
Since the discovery of X-ray diffraction and its potential to elucidate crystal symmetry, powder X-ray diffraction has found diverse applications in the field of pharmaceutical sciences. This review summarizes significant achievements of the technique during various stages of dosage form development. Improved understanding of the principle involved and development of automated hardware and reliable software have led to increased instrumental sensitivity and improved data analysis. These advances continue to expand the applications of powder X-ray diffraction to emerging research fields such as amorphous systems, mechanistic understanding of phase transformations, and "Quality by Design" in formulation development.
Collapse
Affiliation(s)
| | - Roger L Zanon
- Upsher-Smith Laboratories LLC, Maple Grove, Minnesota 55369
| | | | - Seema Thakral
- Characterization Facility, University of Minnesota, Minneapolis, Minnesota 55455.
| |
Collapse
|
13
|
Hadjittofis E, Isbell MA, Karde V, Varghese S, Ghoroi C, Heng JYY. Influences of Crystal Anisotropy in Pharmaceutical Process Development. Pharm Res 2018; 35:100. [PMID: 29556822 PMCID: PMC5859710 DOI: 10.1007/s11095-018-2374-9] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Accepted: 02/19/2018] [Indexed: 01/27/2023]
Abstract
Crystalline materials are of crucial importance to the pharmaceutical industry, as a large number of APIs are formulated in crystalline form, occasionally in the presence of crystalline excipients. Owing to their multifaceted character, crystals were found to have strongly anisotropic properties. In fact, anisotropic properties were found to be quite important for a number of processes including milling, granulation and tableting. An understanding of crystal anisotropy and an ability to control and predict crystal anisotropy are mostly subjects of interest for researchers. A number of studies dealing with the aforementioned phenomena are grounded on over-simplistic assumptions, neglecting key attributes of crystalline materials, most importantly the anisotropic nature of a number of their properties. Moreover, concepts such as the influence of interfacial phenomena in the behaviour of crystalline materials during their growth and in vivo, are still poorly understood. The review aims to address concepts from a molecular perspective, focusing on crystal growth and dissolution. It begins with a brief outline of fundamental concepts of intermolecular and interfacial phenomena. The second part discusses their relevance to the field of pharmaceutical crystal growth and dissolution. Particular emphasis is given to works dealing with mechanistic understandings of the influence of solvents and additives on crystal habit. Furthermore, comments and perspectives, highlighting future directions for the implementation of fundamental concepts of interfacial phenomena in the rational understanding of crystal growth and dissolution processes, have been provided.
Collapse
Affiliation(s)
- Eftychios Hadjittofis
- Surfaces and Particle Engineering Laboratory (SPEL), Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
| | - Mark Antonin Isbell
- Surfaces and Particle Engineering Laboratory (SPEL), Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
| | - Vikram Karde
- Surfaces and Particle Engineering Laboratory (SPEL), Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
| | - Sophia Varghese
- DryProTech Laboratory, Chemical Engineering, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, Gujarat, 382355, India
| | - Chinmay Ghoroi
- DryProTech Laboratory, Chemical Engineering, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, Gujarat, 382355, India
| | - Jerry Y Y Heng
- Surfaces and Particle Engineering Laboratory (SPEL), Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.
| |
Collapse
|
14
|
Abd Rahim S, Amanina Mohamad Adaris N. Effect of crystallization method on the formation of carbamazepine-saccharin co-crystal. MATERIALS TODAY: PROCEEDINGS 2018; 5:22074-22079. [DOI: 10.1016/j.matpr.2018.07.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
|
15
|
Romero DC, Lourenço FR. Measurement uncertainty of dissolution test of acetaminophen immediate release tablets using Monte Carlo simulations. BRAZ J PHARM SCI 2017. [DOI: 10.1590/s2175-97902017000300163] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
16
|
Kohlmann P, Stillhart C, Kuentz M, Parrott N. Investigating Oral Absorption of Carbamazepine in Pediatric Populations. AAPS JOURNAL 2017; 19:1864-1877. [DOI: 10.1208/s12248-017-0149-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/24/2017] [Accepted: 09/14/2017] [Indexed: 11/30/2022]
|
17
|
Feng H, Bondi RW, Anderson CA, Drennen JK, Igne B. Investigation of the Sensitivity of Transmission Raman Spectroscopy for Polymorph Detection in Pharmaceutical Tablets. APPLIED SPECTROSCOPY 2017; 71:1856-1867. [PMID: 28357920 DOI: 10.1177/0003702817690407] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Polymorph detection is critical for ensuring pharmaceutical product quality in drug substances exhibiting polymorphism. Conventional analytical techniques such as X-ray powder diffraction and solid-state nuclear magnetic resonance are utilized primarily for characterizing the presence and identity of specific polymorphs in a sample. These techniques have encountered challenges in analyzing the constitution of polymorphs in the presence of other components commonly found in pharmaceutical dosage forms. Laborious sample preparation procedures are usually required to achieve satisfactory data interpretability. There is a need for alternative techniques capable of probing pharmaceutical dosage forms rapidly and nondestructively, which is dictated by the practical requirements of applications such as quality monitoring on production lines or when quantifying product shelf lifetime. The sensitivity of transmission Raman spectroscopy for detecting polymorphs in final tablet cores was investigated in this work. Carbamazepine was chosen as a model drug, polymorph form III is the commercial form, whereas form I is an undesired polymorph that requires effective detection. The concentration of form I in a direct compression tablet formulation containing 20% w/w of carbamazepine, 74.00% w/w of fillers (mannitol and microcrystalline cellulose), and 6% w/w of croscarmellose sodium, silicon dioxide, and magnesium stearate was estimated using transmission Raman spectroscopy. Quantitative models were generated and optimized using multivariate regression and data preprocessing. Prediction uncertainty was estimated for each validation sample by accounting for all the main variables contributing to the prediction. Multivariate detection limits were calculated based on statistical hypothesis testing. The transmission Raman spectroscopic model had an absolute prediction error of 0.241% w/w for the independent validation set. The method detection limit was estimated at 1.31% w/w. The results demonstrated that transmission Raman spectroscopy is a sensitive tool for polymorphs detection in pharmaceutical tablets.
Collapse
Affiliation(s)
- Hanzhou Feng
- 1 Duquesne University, Graduate School of Pharmaceutical Sciences, Pittsburgh, PA, USA
| | - Robert W Bondi
- 2 GlaxoSmithKline, Analytical Science and Development, King of Prussia, PA, USA
| | - Carl A Anderson
- 1 Duquesne University, Graduate School of Pharmaceutical Sciences, Pittsburgh, PA, USA
| | - James K Drennen
- 1 Duquesne University, Graduate School of Pharmaceutical Sciences, Pittsburgh, PA, USA
| | - Benoît Igne
- 2 GlaxoSmithKline, Analytical Science and Development, King of Prussia, PA, USA
| |
Collapse
|
18
|
|
19
|
Affiliation(s)
- Gerald K. Shiu
- Generic Drugs Research Laboratory, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Washington, District of Columbia
| |
Collapse
|
20
|
Affiliation(s)
- Vinod P. Shah
- Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland
| |
Collapse
|
21
|
Correale J, Chiquete E, Boyko A, Beran RG, Strauch JB, Milojevic S, Frider N. Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod. Drug Des Devel Ther 2016; 10:2109-17. [PMID: 27418809 PMCID: PMC4933568 DOI: 10.2147/dddt.s106802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Both proprietary and nonproprietary medicines are expected to undergo rigorous preapproval testing and both should meet stringent health authority regulatory requirements related to quality to obtain approval. Nonproprietary (also known as copy, or generic) medicines, which base their authorization and use on the proprietary documentation and label, are often viewed as a means to help lower the cost and, thus, increase patient access. If these medicines fail to meet quality standards, such as good manufacturing practice and bioequivalence (in humans), they are then defined as substandard copies and can pose serious risks to patients in terms of safety and efficacy. Potentially noncontrolled or different manufacturing process and excipients in nonproprietary medicines may result in poor batch-to-batch reproducibility (accurate and consistent quantity of each ingredient in each capsule/tablet) and lower quality. Substandard, nonproprietary copies of medicines that are immunomodulatory or immunosuppressive are of concern to patients due to their possible untoward safety and lack of efficacy events. This article reviews the potential risks associated with nonproprietary medicines that do not meet the regulatory requirements of the United States Food and Drug Administration, the European Medicines Agency, or the World Health Organization. The clinical implications for patients are described. This article focuses on nonproprietary medicines for multiple sclerosis, particularly fingolimod, that are not identical to proprietary versions and could thus fail to meet efficacy expectations or have different impact on the safety of patients with multiple sclerosis.
Collapse
Affiliation(s)
- Jorge Correale
- Department of Neurology, Raúl Carrea Institute for Neurological Research, Foundation for the Fight against Infant Neurological Illnesses (FLENI), Buenos Aires, Argentina
| | - Erwin Chiquete
- Department of Neurology and Psychiatry, Salvador Zubirán National Institute of Medical Sciences and Nutrition, Mexico City, Mexico
| | - Alexey Boyko
- Clinical and Research Center “MS and Other Demyelinating Diseases” at the Neuroclinical Hospital, Department of Neurology, Neurosurgery and Medical Genetics of the Pirogov Russian National Research Medical University, Moscow, Russia
| | - Roy G Beran
- South Western Clinical School, University of New South Wales, Liverpool
- Department of Neurology, Liverpool Hospital, Sydney, NSW
- School of Medicine, Griffith University, Southport, QLD, Australia
| | - Jorge Barahona Strauch
- Department of Neurology, Clínica Alemana de Santiago
- School of Medicine, Universidad del Desarrollo, Santiago, Chile
| | | | - Nadina Frider
- Novartis Latin America and Canada Region, Buenos Aires, Argentina
| |
Collapse
|
22
|
Atif M, Azeem M, Sarwar MR. Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature. SPRINGERPLUS 2016; 5:182. [PMID: 27026878 PMCID: PMC4766158 DOI: 10.1186/s40064-016-1824-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Accepted: 02/15/2016] [Indexed: 12/22/2022]
Abstract
Despite the availability of generic antiepileptic drugs (AEDs), still patients and neurologists hesitate to make a switch due to assorted reasons. The objectives of this review were to evaluate the risks associated with the generic substitution of AEDs. In this context, we also summarized the recommendations of various international societies to treat epileptic patients. We used a number of electronic databases to identify the relevant published studies which demonstrated the potential problems and recommendations regarding generic substitution of AEDs. Of 204 articles found initially, 153 were selected for additional review. Subsequently, 68 articles were finally selected. This review concluded that potential problems linked with the generic substitution of AEDs could be bioequivalence issues, failure of drug therapy, emergence of adverse events and increase in the frequency of seizures. The reasons could be the pharmacokinetics properties of AEDs and unique characteristics of some epilepsy patients. Consequently, the generic substitution of AEDs affects the successful treatment and quality of life of the patients. Various guidelines recommend the well-controlled epileptic patients to avoid switching from brand-to-generic products, generic-to-brand products or generic to some other generic products.
Collapse
Affiliation(s)
- Muhammad Atif
- Department of Pharmacy, Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Bahawalpur, Punjab Pakistan
| | - Muhammad Azeem
- Department of Pharmacy, Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Bahawalpur, Punjab Pakistan
| | - Muhammad Rehan Sarwar
- Department of Pharmacy, Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Bahawalpur, Punjab Pakistan
| |
Collapse
|
23
|
Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs. Molecules 2015; 20:18759-76. [PMID: 26501244 PMCID: PMC6331817 DOI: 10.3390/molecules201018759] [Citation(s) in RCA: 201] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2015] [Revised: 10/06/2015] [Accepted: 10/08/2015] [Indexed: 01/14/2023] Open
Abstract
Drugs with low water solubility are predisposed to poor and variable oral bioavailability and, therefore, to variability in clinical response, that might be overcome through an appropriate formulation of the drug. Polymorphs (anhydrous and solvate/hydrate forms) may resolve these bioavailability problems, but they can be a challenge to ensure physicochemical stability for the entire shelf life of the drug product. Since clinical failures of polymorph drugs have not been uncommon, and some of them have been entirely unexpected, the Food and Drug Administration (FDA) and the International Conference on Harmonization (ICH) has required preliminary and exhaustive screening studies to identify and characterize all the polymorph crystal forms for each drug. In the past, the polymorphism of many drugs was detected fortuitously or through manual time consuming methods; today, drug crystal engineering, in particular, combinatorial chemistry and high-throughput screening, makes it possible to easily and exhaustively identify stable polymorphic and/or hydrate/dehydrate forms of poorly soluble drugs, in order to overcome bioavailability related problems or clinical failures. This review describes the concepts involved, provides examples of drugs characterized by poor solubility for which polymorphism has proven important, outlines the state-of-the-art technologies and discusses the pertinent regulations.
Collapse
|
24
|
Ullah M, Hussain I, Sun CC. The development of carbamazepine-succinic acid cocrystal tablet formulations with improved in vitro and in vivo performance. Drug Dev Ind Pharm 2015; 42:969-76. [PMID: 26460090 DOI: 10.3109/03639045.2015.1096281] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The use of soluble cocrystal for delivering drugs with low solubility, although a potentially effective approach, often suffers the problem of rapid disproportionation during dissolution, which negates the solubility advantages offered by the cocrystal. This necessitates their robust stabilization in order for successful use in a tablet dosage form. The cocrystal between carbamezepine and succinic acid (CBZ-SUC) exhibits a higher aqueous solubility than its dihydrate, which is the stable form of CBZ in water. Using this model system, we demonstrate an efficient and material-sparing tablet formulation screening approach enabled by intrinsic dissolution rate measurements. Three tablet formulations capable of stabilizing the cocrystal both under accelerated condition of 40 °C and 75% RH and during dissolution were developed using three different polymers, Soluplus® (F1), Kollidon VA/64 (F2) and Hydroxypropyl methyl cellulose acetate succinate (F3). When compared to a marketed product, Epitol® 200 mg tablets (F0), drug release after 60 min from formulations F1 (∼82%), F2 (∼95%) and F3 (∼95%) was all higher than that from Epitol® (79%) in a modified simulated intestinal fluid. Studies in albino rabbits show correspondingly better bioavailability of F1-F3 than Epitol.
Collapse
Affiliation(s)
- Majeed Ullah
- a Department of Pharmacy , COMSATS Institute of Information Technology , Abbottabad , Pakistan and.,b Department of Pharmaceutics , Pharmaceutical Materials Science and Engineering Laboratory, College of Pharmacy, University of Minnesota , Minneapolis , MN , USA
| | - Izhar Hussain
- a Department of Pharmacy , COMSATS Institute of Information Technology , Abbottabad , Pakistan and
| | - Changquan Calvin Sun
- b Department of Pharmaceutics , Pharmaceutical Materials Science and Engineering Laboratory, College of Pharmacy, University of Minnesota , Minneapolis , MN , USA
| |
Collapse
|
25
|
Paudel A, Raijada D, Rantanen J. Raman spectroscopy in pharmaceutical product design. Adv Drug Deliv Rev 2015; 89:3-20. [PMID: 25868453 DOI: 10.1016/j.addr.2015.04.003] [Citation(s) in RCA: 168] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Revised: 03/15/2015] [Accepted: 04/01/2015] [Indexed: 12/20/2022]
Abstract
Almost 100 years after the discovery of the Raman scattering phenomenon, related analytical techniques have emerged as important tools in biomedical sciences. Raman spectroscopy and microscopy are frontier, non-invasive analytical techniques amenable for diverse biomedical areas, ranging from molecular-based drug discovery, design of innovative drug delivery systems and quality control of finished products. This review presents concise accounts of various conventional and emerging Raman instrumentations including associated hyphenated tools of pharmaceutical interest. Moreover, relevant application cases of Raman spectroscopy in early and late phase pharmaceutical development, process analysis and micro-structural analysis of drug delivery systems are introduced. Finally, potential areas of future advancement and application of Raman spectroscopic techniques are discussed.
Collapse
|
26
|
Monitoring of multiple solid-state transformations at tablet surfaces using multi-series near-infrared hyperspectral imaging and multivariate curve resolution. Eur J Pharm Biopharm 2015; 93:224-30. [DOI: 10.1016/j.ejpb.2015.03.034] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2014] [Revised: 01/30/2015] [Accepted: 03/30/2015] [Indexed: 11/19/2022]
|
27
|
Jankovic SM, Ignjatovic Ristic D. Is bioavailability altered in generic versus brand anticonvulsants? Expert Opin Drug Metab Toxicol 2014; 11:329-32. [DOI: 10.1517/17425255.2015.989211] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
28
|
An Integrated Process Analytical Technology (PAT) Approach for Pharmaceutical Crystallization Process Understanding to Ensure Product Quality and Safety: FDA Scientist’s Perspective. Org Process Res Dev 2014. [DOI: 10.1021/op500056a] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Santos OMM, Reis MED, Jacon JT, Lino MEDS, Simões JS, Doriguetto AC. Polymorphism: an evaluation of the potential risk to the quality of drug products from the Farmácia Popular Rede Própria. BRAZ J PHARM SCI 2014. [DOI: 10.1590/s1984-82502011000100002] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Polymorphism in solids is a common phenomenon in drugs, which can lead to compromised quality due to changes in their physicochemical properties, particularly solubility, and, therefore, reduce bioavailability. Herein, a bibliographic survey was performed based on key issues and studies related to polymorphism in active pharmaceutical ingredient (APIs) present in medications from the Farmácia Popular Rede Própria. Polymorphism must be controlled to prevent possible ineffective therapy and/or improper dosage. Few mandatory tests for the identification and control of polymorphism in medications are currently available, which can result in serious public health concerns.
Collapse
|
30
|
Sander JW, Ryvlin P, Stefan H, Booth DR, Bauer J. Generic substitution of antiepileptic drugs. Expert Rev Neurother 2014; 10:1887-98. [DOI: 10.1586/ern.10.163] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
31
|
Heigl N, Koller DM, Glasser BJ, Muzzio FJ, Khinast JG. Quantitative on-line vs. off-line NIR analysis of fluidized bed drying with consideration of the spectral background. Eur J Pharm Biopharm 2013; 85:1064-74. [DOI: 10.1016/j.ejpb.2013.09.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2012] [Revised: 08/23/2013] [Accepted: 09/11/2013] [Indexed: 10/26/2022]
|
32
|
Li M, Qiao N, Wang K. Influence of sodium lauryl sulfate and tween 80 on carbamazepine-nicotinamide cocrystal solubility and dissolution behaviour. Pharmaceutics 2013; 5:508-24. [PMID: 24300560 PMCID: PMC3873677 DOI: 10.3390/pharmaceutics5040508] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Revised: 09/05/2013] [Accepted: 09/29/2013] [Indexed: 12/02/2022] Open
Abstract
The influence of the surfactants of sodium lauryl sulfate (SLS) and Tween 80 on carbamazepine–nicotinamide (CBZ–NIC) cocrystal solubility and dissolution behaviour has been studied in this work. The solubility of the CBZ–NIC cocrystal was determined by measuring the eutectic concentrations of the drug and the coformer. Evolution of the intrinsic dissolution rate (IDR) of the CBZ–NIC cocrystal was monitored by the UV imaging dissolution system during dissolution. Experimental results indicated that SLS and Tween 80 had little influence upon the solubility of the CBZ–NIC cocrystal but they had totally opposite effects on the IDR of the CBZ–NIC cocrystal during dissolution. SLS significantly increased the IDR of the CBZ–NIC cocrystal while Tween 80 decreased its IDR.
Collapse
Affiliation(s)
- Mingzhong Li
- School of Pharmacy, De Montfort University, Leicester LE1 9BH, UK.
| | | | | |
Collapse
|
33
|
Thakral NK, Ragoonanan V, Suryanarayanan R. Quantification, Mechanism, and Mitigation of Active Ingredient Phase Transformation in Tablets. Mol Pharm 2013; 10:3128-36. [DOI: 10.1021/mp400180n] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Naveen K. Thakral
- Department of Pharmaceutics,
College
of Pharmacy, University of Minnesota, 9-177 WDH, 308 Harvard Street
S.E., Minneapolis, Minnesota 55455, United States
| | - Vishard Ragoonanan
- Department of Pharmaceutics,
College
of Pharmacy, University of Minnesota, 9-177 WDH, 308 Harvard Street
S.E., Minneapolis, Minnesota 55455, United States
| | - Raj Suryanarayanan
- Department of Pharmaceutics,
College
of Pharmacy, University of Minnesota, 9-177 WDH, 308 Harvard Street
S.E., Minneapolis, Minnesota 55455, United States
| |
Collapse
|
34
|
Medina JR, Salazar DK, Hurtado M, Cortés AR, Domínguez-Ramírez AM. Comparative in vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow-through cell system. Saudi Pharm J 2013; 22:141-7. [PMID: 24648826 DOI: 10.1016/j.jsps.2013.02.001] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2012] [Accepted: 02/04/2013] [Indexed: 10/27/2022] Open
Abstract
Dissolution profiles of four carbamazepine immediate-release generic products (200 mg tablets) and the reference product Tegretol® were evaluated using the USP paddles method and an alternative method with the flow-through cell system, USP Apparatus 4. Under official conditions all products met the Q specification, dissolution profiles of generic products were similar to the dissolution profile of the reference product (f 2 > 50) and model-independent parameters showed non significant differences to the reference product except mean dissolution time for product A (p < 0.05). On the other hand, when the flow-through cell system was used, none of the products met the pharmacopeial specification at 15 min and product A did not reach dissolution criteria at 60 min, dissolution profiles of all generic products were not similar to the reference product profile (f 2 < 50) and all model-independent parameters showed significant differences compared to the reference product (p < 0.05). Weibull's model was more useful for adjusting the dissolution data of all products in both USP apparatuses and Td values showed significant differences compared to the reference product (p < 0.05) when USP Apparatus 4 was used. These results indicate that the proposed method, using the flow-through cell system, is more discriminative in evaluating both, rate and extent of carbamazepine dissolution process from immediate-release generic products.
Collapse
Affiliation(s)
- José Raúl Medina
- Departamento Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Mexico
| | - Dulce Karina Salazar
- Departamento Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Mexico
| | - Marcela Hurtado
- Departamento Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Mexico
| | - Alma Rosa Cortés
- Departamento Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Mexico
| | | |
Collapse
|
35
|
Stockmann C, Spigarelli MG, Ampofo K, Sherwin CM. Bioequivalence and Bioavailability Clinical Trials: A Status Report from the National Institutes of Health ClinicalTrials.gov Registry. ACTA ACUST UNITED AC 2013; 5:244-247. [PMID: 25328346 PMCID: PMC4201122 DOI: 10.4172/jbb.1000167] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Drug development is an expensive process that is marked by a high-failure rate. For this reason early stage bioequivalence and pharmacokinetic studies are essential in determining the fate of new drug products. In this study, we sought to systematically assess the current trends of ongoing and recently completed bioequivalence and bioavailability trials that have been registered within a national clinical trials registry. All bioequivalence and bioavailability studies registered in the United States ClinicalTrials.gov registry from late-2007 through 2011 were identified. Over this period, more than 2300 interventional bioequivalence and bioavailability trials were registered. As of 2013, the vast majority of studies (86%) have been completed, 10% are actively recruiting participants, and the remainder are engaged in data analysis (4%). When compared to completed trials, ongoing trials are in later phases of clinical development, recruiting larger numbers of participants, and more likely to recruit women and children (P<0.001 for all). These data suggest that the quality of bioequivalence and bioavailability studies has improved rapidly, even over the last five years. However, further work is needed to sustain – and accelerate – these improvements in the design of bioequivalence and bioavailability studies to ensure that safe and efficacious medicines swiftly reach healthcare providers and their patients.
Collapse
Affiliation(s)
- Chris Stockmann
- Department of Pediatrics, University of Utah School of Medicine, USA ; Department of Pharmacology/Toxicology, University of Utah College of Pharmacy, USA
| | - Michael G Spigarelli
- Department of Pediatrics, University of Utah School of Medicine, USA ; Department of Pharmacology/Toxicology, University of Utah College of Pharmacy, USA
| | - Krow Ampofo
- Department of Pediatrics, University of Utah School of Medicine, USA
| | - Catherine Mt Sherwin
- Department of Pediatrics, University of Utah School of Medicine, USA ; Department of Pharmacology/Toxicology, University of Utah College of Pharmacy, USA
| |
Collapse
|
36
|
Qiao N, Wang K, Schlindwein W, Davies A, Li M. In situ monitoring of carbamazepine-nicotinamide cocrystal intrinsic dissolution behaviour. Eur J Pharm Biopharm 2012; 83:415-26. [PMID: 23159709 DOI: 10.1016/j.ejpb.2012.10.005] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Revised: 10/17/2012] [Accepted: 10/21/2012] [Indexed: 10/27/2022]
Abstract
Cocrystals have shown huge potential to improve the dissolution rate and absorption of a poorly water soluble drug. However, solution mediated phase transformation of cocrystals could greatly reduce the enhancement of its apparent solubility and dissolution rate. The aim of this study is to gain a deep understanding of the phase transition behaviour of cocrystals during dissolution and to investigate the improvement of dissolution rate. Dissolution and transformation behaviour of carbamazepine-nicotinamide (CBZ-NIC) cocrystal, physical mixture and different forms of carbamazepine: form I (CBZ I), form III (CBZ III) and dihydrate (CBZ DH) were studied by different in situ techniques of UV imaging and Raman spectroscopy. It has been found that compared with CBZ III and I, the rate of intrinsic dissolution rate (IDR) of CBZ-NIC cocrystal decreases slowly during dissolution, indicating the rate of crystallisation of CBZ DH from the solution is slow. In situ solid-state characterisation has shown the evolution of conversion of CBZ-NIC cocrystal and polymorphs to its dihydrate form. The study has shown that in situ UV imaging and Raman spectroscopy with a complementary technique of SEM can provide an in depth understanding during dissolution of cocrystals.
Collapse
Affiliation(s)
- Ning Qiao
- School of Pharmacy, De Montfort University, Leicester, UK
| | | | | | | | | |
Collapse
|
37
|
|
38
|
Kachrimanis K, Griesser UJ. Dehydration Kinetics and Crystal Water Dynamics of Carbamazepine Dihydrate. Pharm Res 2012; 29:1143-57. [DOI: 10.1007/s11095-012-0698-4] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2011] [Accepted: 01/27/2012] [Indexed: 11/29/2022]
|
39
|
Recrystallization of commercial carbamazepine samples-a strategy to control dissolution variability. Pharmaceutics 2012; 4:58-70. [PMID: 24300180 PMCID: PMC3834897 DOI: 10.3390/pharmaceutics4010058] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2011] [Revised: 01/09/2012] [Accepted: 01/10/2012] [Indexed: 11/17/2022] Open
Abstract
Physical properties of commercial carbamazepine (CBZ) samples can significantly influence drug release and thereby jeopardize bioequivalence of the final dosage form. The aim of this study was to reduce variability in commercial CBZ samples by recrystallization. CBZ samples of four different suppliers were recrystallized in ethanol solution containing 1% polyvinylpyrrolidone (PVP). CBZ samples were analyzed by disk intrinsic dissolution rate (DIDR), X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and scanning electron microscopy (SEM). Recrystallized CBZ samples showed strongly reduced variability in DIDR compared to the untreated CBZ samples. Moreover, transformation process to CBZ dihydrate was inhibited; no dihydrate crystals were visible on compact surfaces after 8 h intrinsic dissolution measurement. Recrystallized CBZ samples showed no change in polymorphic form, however, particle size and shape was inhomogenous. In binary mixtures with microcrystalline cellulose, recrystallized CBZ samples again showed difference in drug release. This difference was associated with the inhomogenous particle size in the recrystallized CBZ samples. The results show that a controlled grinding step is required after recrystallization. We suggest the recrystallization in presence of 1% PVP followed by a controlled grinding step as a strategy to reduce dissolution variability in commercial CBZ samples.
Collapse
|
40
|
Acevedo C, Acevedo K. Epilepsy treatment in developing countries: drug treatment. HANDBOOK OF CLINICAL NEUROLOGY 2012; 108:925-941. [PMID: 22939076 DOI: 10.1016/b978-0-444-52899-5.00038-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Affiliation(s)
- Carlos Acevedo
- University of Los Andes, Clínica Alemana, Alemana, Santiago, Chile.
| | | |
Collapse
|
41
|
Greco K, Bogner R. Solution-mediated phase transformation: significance during dissolution and implications for bioavailability. J Pharm Sci 2011; 101:2996-3018. [PMID: 22213419 DOI: 10.1002/jps.23025] [Citation(s) in RCA: 96] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2011] [Revised: 10/31/2011] [Accepted: 12/02/2011] [Indexed: 11/10/2022]
Abstract
Solubility improvement of poorly soluble drug compounds is a key approach to ensuring the successful development of many new drugs. Methods used to improve the solubility of drug compounds include forming a salt, cocrystal, or amorphous solid. These methods of improving solubility can often lead to a phenomenon called solution-mediated phase transformation, a phase change that is facilitated through exposure to solution. Solution-mediated phase transformation occurs in three steps: dissolution to create a supersaturated solution followed by nucleation of less soluble phase and the growth of that phase. When the growth of the less soluble phase occurs on the surface of the metastable solid, this phenomenon can cause a marked decrease in dissolution rate during in vitro dissolution evaluation, and ultimately in vivo. Therefore, transformation to a less soluble solid during dissolution is an important aspect to consider when evaluating approaches to increase the solubility of a poorly soluble drug. Identification of solution-mediated phase transformation during dissolution is reviewed for powder dissolution, rotating disk method, and channel flow-through apparatus. Types of solution-mediated phase transformation are described in this report, including those involving salts, polymorphs, amorphous solids, and cocrystals. Many experimental examples are provided. Evidence of potential solution-mediated phase transformation in vivo is discussed to better understand the relationship between in vitro dissolution evaluation and in vivo performance.
Collapse
Affiliation(s)
- Kristyn Greco
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut 06269, USA
| | | |
Collapse
|
42
|
Xu C, Zou M, Liu Y, Ren J, Tian Y, Yan J, Wang Y, Cheng G. Pharmacokinetics of carbamazepine polymorphs and dihydrate in rats, related to dogs and humans. Arch Pharm Res 2011; 34:1973-82. [DOI: 10.1007/s12272-011-1118-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2011] [Revised: 06/18/2011] [Accepted: 06/30/2011] [Indexed: 11/24/2022]
|
43
|
Flicker F, Betz G. Effect of crospovidone and hydroxypropyl cellulose on carbamazepine in high-dose tablet formulation. Drug Dev Ind Pharm 2011; 38:697-705. [DOI: 10.3109/03639045.2011.623166] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
44
|
Abstract
The present investigation is aimed to prepare the porous microspheres of carbamazepine using eudragit as release retardant, compritol as core forming agent, and HPMC as re-crystallization inhibitor for short-term sustained delivery of carbamazepine. The proposed microspheres were formulated using the emulsion solvent diffusion method. The obtained microspheres were characterized for its particle size distribution, thermal analysis (DSC), crystallinity (PXRD), surface morphology (SEM), and in vitro drug release. The prepared microspheres were found to be optimal in terms of particle size and entrapment efficacy. However, the obtained entrapment efficacy is insufficient to deliver the high dose drug such as carbamazepine. There were no compatibility issues and the drug is partially present in crystalline form in microspheres, which were confirmed by DSC and PXRD, respectively. The time to release 50% of drug from microspheres were in the range of 0.5 - 3.0 h, which could be used to prevent the formation of dihydrate and high extent of drug release. Further investigations are required to reduce the amount of polymer in microspheres that can provide maximum drug loading and acceptable dosage form.
Collapse
Affiliation(s)
- M Rajkumar
- Department of Biopharmaceutics, Biopharmaceutical Research Group, Government College of Pharmacy, Karad, India
| | | |
Collapse
|
45
|
Flicker F, Eberle VA, Betz G. Variability in commercial carbamazepine samples – Impact on drug release. Int J Pharm 2011; 410:99-106. [DOI: 10.1016/j.ijpharm.2011.03.032] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2010] [Revised: 03/01/2011] [Accepted: 03/13/2011] [Indexed: 10/18/2022]
|
46
|
|
47
|
Critical factors in manufacturing multi-layer tablets—Assessing material attributes, in-process controls, manufacturing process and product performance. Int J Pharm 2010; 398:9-13. [DOI: 10.1016/j.ijpharm.2010.07.025] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2010] [Revised: 07/13/2010] [Accepted: 07/17/2010] [Indexed: 11/20/2022]
|
48
|
Ruiz ME, Conforti P, Fagiolino P, Volonté MG. The use of saliva as a biological fluid in relative bioavailability studies: comparison and correlation with plasma results. Biopharm Drug Dispos 2010; 31:476-85. [DOI: 10.1002/bdd.728] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2010] [Revised: 08/06/2010] [Accepted: 08/27/2010] [Indexed: 11/08/2022]
|
49
|
Chakravarty P, Govindarajan R, Suryanarayanan R. Investigation of Solution and Vapor Phase Mediated Phase Transformation in Thiamine Hydrochloride. J Pharm Sci 2010; 99:3941-52. [DOI: 10.1002/jps.22240] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
50
|
Jeong SH, Youn YS, Shin BS, Park ES. Drug Polymorphism and its Importance on Drug Development Process. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2010. [DOI: 10.4333/kps.2010.40.s.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|